Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
about
UK guidelines for the management of soft tissue sarcomasUK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Phase II studies in soft tissue sarcoma: time for reappraisal.Tumor volume as an alternative response measurement for imatinib treated GIST patients.Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinibA phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelinesVariability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentSurgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib.Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?Phase II clinical trials in oncology: are we hitting the target?Imatinib mesylate for the treatment of gastrointestinal stromal tumor.Response assessment in gastrointestinal stromal tumor.Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST.Moving beyond response criteria: new measures of success in the treatment of sarcomas.Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.Recent advances in managing gastrointestinal stromal tumor.Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib.Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q28076730-C42E0867-E45B-4931-AD61-FF86F54EA54AQ33612778-C39FED38-4A69-4B37-AC9A-FADC684D9219Q33921067-3704893A-222B-446A-95ED-7502100EF58AQ34143849-E7D4FD99-C164-4AE5-BB69-458FBF7C7161Q34469701-B8FB6061-842E-43B7-8C53-05964BE506B0Q34566471-36E622A1-56C4-4040-85D6-2A0DECD834C8Q34628840-4E8B5043-9A89-4F91-A1EF-E943CEC6D519Q34636081-8788F035-A32F-4810-A876-6480AC725242Q34672344-98A2C91B-4D3E-4564-946A-74A49CD7833BQ35170251-C2FC154F-AA16-4ACA-9D68-001846245518Q35958048-9BC97746-F072-423E-8079-1BC6BF54021BQ36173335-85FD81FC-F3D4-4FDC-B47D-2D0DB89CF790Q37131713-7D9C3940-10C9-4A6B-B7F6-8883CA232BA2Q37238580-7EEC7AC8-09E5-492E-9C26-8EC1FDF9BFE3Q37342226-5585EE50-4C3D-4B87-A4F2-BF9FE1B6B672Q37705422-506F354C-C633-47D5-B1A8-E23B77157918Q37752353-79115780-503A-4C13-A4F1-AFE9DA37A831Q37801348-CD083A49-EF21-48E0-981D-F879E9FDA39DQ37988591-F28F201C-EA95-48CA-8876-8D2000E76601Q38014354-87C9568C-19B5-4987-AEA2-24622B345A31Q38055499-14A8ED9B-161A-4B06-B0E3-3B331166C773Q38090985-8F596C4B-6BBB-4C2F-B829-42B33663125DQ39683594-92D67E5F-B257-40DA-86CD-75FD64282758Q41725812-9170B277-ADFF-456F-B308-EDC6A388D621Q44612900-D8E54C31-6014-49D7-9FFF-30EF7B5BC619Q45060332-6225CD4A-9DD6-4FFC-AEC2-D4E65D00341EQ47097647-F86A3B6E-E4E7-4DCB-9F6F-736D3BB14C59Q50913835-A0C1D749-F494-4FDB-BDBC-B61CAFB03D92Q52587191-F965171A-6608-4D69-8320-5B327FDA11D2Q55384540-403D9383-BBC8-41E2-9F07-B1E239F3EBAAQ57570640-F94897B0-0981-4432-816F-75E3DFADFA8E
P2860
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@ast
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@en
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@nl
type
label
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@ast
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@en
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@nl
prefLabel
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@ast
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@en
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@nl
P2093
P2860
P50
P356
P1476
Absence of progression as asse ...... RTC-ISG-AGITG phase III trial.
@en
P2093
Ian Judson
Jaap Verweij
Martine Van Glabbeke
Michael Findlay
Pancras C W Hogendoorn
Peter Reichardt
Rolf Issels
Serge Leyvraz
P2860
P304
P356
10.1200/JCO.2008.21.3330
P407
P577
2009-07-20T00:00:00Z